Last reviewed 2026-04-20 · How we verify

Chlormethylenecycline (CLOMOCYCLINE)

Phase 2 active Small molecule

Chlormethylenecycline (generic name: CLOMOCYCLINE) is a clomocycline drug. It is currently in Phase 2 development.

Clomocycline works by interfering with bacterial DNA replication, ultimately inhibiting the growth and spread of bacteria.

Chlormethylenecycline, also known as Clomocycline, is a small molecule antibiotic in the clomocycline drug class. Its mechanism of action is not well-documented, but it is believed to target bacterial DNA replication. Clomocycline is not FDA-approved for any indications, and its commercial status is unknown. As a result, there is limited information available on its safety profile and potential side effects. Further research is needed to fully understand the properties and potential uses of Clomocycline.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLOMOCYCLINE
Drug class	clomocycline
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like factories that make copies of themselves. Bacteria are like tiny factories that make copies of themselves too, but they can cause harm. Clomocycline is like a tool that disrupts the bacterial factories, making it harder for them to make copies of themselves and eventually killing them off.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chlormethylenecycline CI brief — competitive landscape report
Chlormethylenecycline updates RSS · CI watch RSS

Frequently asked questions about Chlormethylenecycline

What is Chlormethylenecycline?

Chlormethylenecycline (CLOMOCYCLINE) is a clomocycline drug.

How does Chlormethylenecycline work?

Clomocycline works by interfering with bacterial DNA replication, ultimately inhibiting the growth and spread of bacteria.

What is the generic name of Chlormethylenecycline?

CLOMOCYCLINE is the generic (nonproprietary) name of Chlormethylenecycline.

What drug class is Chlormethylenecycline in?

Chlormethylenecycline belongs to the clomocycline class. See all clomocycline drugs at /class/clomocycline.

What development phase is Chlormethylenecycline in?

Chlormethylenecycline is in Phase 2.

Drug class: All clomocycline drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing